Key takeaways
- ~1 in 50,000 Estimated US HAE prevalence (HAEA) — Type I C1-INH deficiency ~85%, Type II dysfunction ~15%
- ~97% Share of HAE episodes that are cutaneous or abdominal swellings · Bork, Am J Med 2006 (PMID 16490473)
- 0.9% Share of episodes that are laryngeal — rare but the leading cause of HAE death, chiefly in undiagnosed patients · Bork, Am J Med 2006 (PMID 16490473); Bork, JACI 2012 (PMID 22841766)
Hereditary angioedema affects an estimated 1 in 50,000 Americans; the diagnostic delay, not drug supply, drives HAE's 0.9% laryngeal-attack mortality risk in undiagnosed patients.
Hereditary angioedema (HAE) is an autosomal-dominant disorder of the SERPING1 gene that reduces the quantity (Type I, ~85% of patients) or function (Type II, ~15%) of C1-esterase inhibitor. The resulting loss of control over the contact and complement systems drives unchecked plasma-kallikrein activity and bradykinin overproduction — the mediator of recurrent, non-pruritic, non-urticarial swelling. US prevalence is estimated at roughly 1 in 50,000 (a US HAE Association patient-advocacy estimate, not a peer-reviewed count), and because inheritance is autosomal dominant, each child of an affected parent has a 50% risk.
Attacks begin early, with mean symptom onset around age 11, and recur for life. In a 221-patient natural-history cohort spanning 131,110 episodes, cutaneous and abdominal swellings made up 97.4% of all attacks, while laryngeal episodes were only 0.9% yet carry the disease's mortality. Abdominal attacks (crampy pain, vomiting in 73%, diarrhoea in 41%) mimic an acute abdomen and precede skin swelling in a substantial minority, driving unnecessary surgery and years of misdiagnosis. Laryngeal attacks cause death by asphyxiation disproportionately in patients whose HAE has never been diagnosed, making earlier recognition, not new therapy, the pivotal lever. Diagnosis rests on a low C4 with reduced C1-INH antigenic level (Type I) or reduced C1-INH function with normal antigen (Type II).
HAE attack types — distribution, burden and clinical implication
| Attack Type | Share of Episodes | Typical Features | Clinical Burden | Diagnostic / Management Implication |
|---|---|---|---|---|
| Cutaneous swelling | With abdominal, ~97% of episodes combined | Non-pruritic, non-pitting swelling of extremities, face, genitals, trunk; no urticaria | Disfigurement and functional impairment; episodes last ~2–5 days | Absence of wheals/urticaria distinguishes HAE from histaminergic (allergic) angioedema |
| Abdominal attacks | With cutaneous, ~97% of episodes combined | Crampy pain (mean score 8.4/10), vomiting 73%, diarrhoea 41%; can precede skin swelling | Mimics acute abdomen — unnecessary laparotomy; circulatory collapse in ~4% | Recognise as HAE to avoid needless surgery · Bork, Am J Gastroenterol 2006 (PMID 16464219) |
| Laryngeal attacks | 0.9% of episodes | Upper-airway obstruction; hoarseness, dysphagia, progressive dyspnea | Life-threatening asphyxiation; leading cause of HAE death, concentrated in undiagnosed patients | Drives urgency of diagnosis and on-demand rescue access · Bork, JACI 2012 (PMID 22841766) |
| Lifetime course | Mean onset ~age 11; recurrent for life | Relapsing episodes; women more severely affected on average | Chronic, unpredictable burden across cutaneous, abdominal and laryngeal sites | Attack frequency and severity determine long-term prophylaxis candidacy |
Sources: Bork K et al. Am J Med 2006 (PMID 16490473), symptoms, affected organs and course; Bork K et al. Am J Gastroenterol 2006 (PMID 16464219), abdominal attacks; Bork K et al. J Allergy Clin Immunol 2012 (PMID 22841766), fatal laryngeal attacks and mortality; Zuraw BL. N Engl J Med 2008 (PMID 18768946), HAE clinical review.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- How large is the US HAE population, and how does the Type I / Type II and severity split shape the addressable prophylaxis pool? • US prevalence triangulation and the estimate basis • Type I (~85%) vs Type II (~15%) breakdown • severity stratification (attack frequency) that determines prophylaxis candidacy
- What does the HAE attack burden actually look like across cutaneous, abdominal and laryngeal attacks, and where does it drive cost and risk? • Attack-type distribution from natural-history data • abdominal-attack burden and its acute-abdomen misdiagnosis pathway • laryngeal mortality concentrated in undiagnosed patients
- Where is the diagnostic delay in US HAE, and what is the untreated / undiagnosed pool worth commercially? • Diagnostic pathway (C4, C1-INH antigenic and functional testing) • recognition gaps in emergency and primary care • the undiagnosed pool as the strategic expansion lever
What's inside
-
1 · A Single SERPING1 Mutation Cuts C1-Inhibitor Function, Passing a 50% Inheritance Risk to Each Child 4 pp
- Why Type I C1-INH deficiency (85%) and Type II dysfunction (15%) require different confirmatory tests despite one shared gene.
- How a 50% inheritance risk per child turns HAE from an individual diagnosis into a family-wide identification challenge.
-
2 · Type I C1-INH Deficiency Accounts for 85% of US HAE Cases, Type II Just 15% 3 pp
- Why Type I's low C1-INH antigen and Type II's normal antigen with low function require two separate confirmatory tests.
- How the 85%-to-15% split between Type I and Type II C1-INH deficiency shapes which lab assay confirms disease first.
-
3 · US HAE Prevalence Is Estimated at 1 in 50,000, a Patient-Advocacy Figure Not Yet Peer-Reviewed 4 pp
- Why the roughly 1-in-50,000 US prevalence figure comes from the HAE Association, not a peer-reviewed epidemiological study.
- What triangulating a patient-advocacy prevalence estimate against clinical literature reveals about the true addressable US prophylaxis population.
-
4 · Cutaneous and Abdominal Attacks Make Up 97% of HAE Episodes, Laryngeal Just 0.9% 6 pp
- How a 221-patient natural-history cohort spanning 131,110 episodes established the 97.4% cutaneous-and-abdominal share of attacks.
- Why laryngeal attacks account for only 0.9% of episodes yet carry nearly all of HAE's attack-related mortality risk.
-
5 · Abdominal Attacks Mimic an Acute Abdomen in Up to 73% of Episodes, Delaying HAE Diagnosis 5 pp
- Why crampy pain scoring 8.4 out of 10, vomiting in 73%, and diarrhoea in 41% push abdominal attacks toward surgery.
- How mistaking abdominal HAE attacks for an acute abdomen leads to unnecessary laparotomy instead of bradykinin-pathway treatment.
-
6 · Laryngeal Mortality in HAE Concentrates in Patients Who Were Never Diagnosed 4 pp
- Why laryngeal asphyxiation deaths in HAE concentrate specifically among patients whose disease was never diagnosed.
- How a low-C4 test paired with C1-INH antigen or function assay could close the recognition gap before a fatal attack.
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx US Hereditary Angioedema Disease Landscape is built for commercial, medical affairs, and epidemiology teams that need a rigorous, evidence-based characterisation of the US HAE patient population. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify indication, geography, and epidemiological focus.
- 2. Scoping callAXLRx analyst confirms subpopulation scope, data sources, and delivery format.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
Every AXLRx assessment is built from primary sources: peer-reviewed literature, regulatory databases, and disease-registry data, not secondary summaries or market-research reports. Epidemiological estimates are triangulated and labelled by source type; any figure that cannot be sourced to a live record does not ship, and patient-advocacy estimates are identified as such rather than presented as peer-reviewed counts.
US Hereditary Angioedema Disease Landscape sources: Zuraw BL, N Engl J Med 2008 (PMID 18768946) for pathophysiology, the Type I/II split and diagnostic criteria; Bork K et al., Am J Med 2006 (PMID 16490473) and Am J Gastroenterol 2006 (PMID 16464219) for attack distribution and abdominal-attack burden; Bork K et al., J Allergy Clin Immunol 2012 (PMID 22841766) for laryngeal mortality; and the US HAE Association for the prevalence estimate.
- Pathophysiology, Type I/II split, and diagnostic criteria (low C4; C1-INH antigenic vs functional) verified against Zuraw BL, NEJM 2008 (PMID 18768946)
- Attack distribution (cutaneous + abdominal ~97% of episodes; laryngeal 0.9%; mean onset ~age 11) verified against Bork et al., Am J Med 2006 (PMID 16490473)
- Abdominal-attack features (vomiting 73%, diarrhoea 41%) verified against Bork et al., Am J Gastroenterol 2006 (PMID 16464219)
- Laryngeal mortality concentrated in undiagnosed patients verified against Bork et al., JACI 2012 (PMID 22841766)
- US prevalence (~1 in 50,000) labelled as a US HAE Association patient-advocacy estimate, not a peer-reviewed count
Frequently asked questions
Disease What causes hereditary angioedema, and how do Type I and Type II differ?
HAE is an autosomal-dominant SERPING1 disorder that reduces C1-esterase inhibitor, leading to unchecked plasma-kallikrein activity and bradykinin-driven swelling. Type I (~85% of patients) has low C1-INH levels; Type II (~15%) has normal or elevated but dysfunctional C1-INH. Both present with recurrent non-urticarial swelling and are distinct from histaminergic (allergic) angioedema. Diagnosis rests on a low C4 with C1-INH antigenic and functional testing.
Burden How severe is the HAE attack burden, and which attacks are dangerous?
Attacks begin around age 11 and recur for life. In natural-history data, cutaneous and abdominal swellings account for about 97% of episodes; abdominal attacks cause crampy pain with vomiting in roughly three-quarters of episodes and are frequently misdiagnosed as an acute abdomen. Laryngeal attacks are under 1% of episodes but are the leading cause of HAE death by asphyxiation — a risk concentrated in patients whose HAE has never been diagnosed.
Deliverables What formats are included with every assessment?
Every commissioned assessment includes three deliverables: a 20–30 page PDF analyst assessment with verified sources and exhibit tables, an editable Excel model, and a 10–15 slide PowerPoint readout deck. An optional 60-minute analyst readout call is included with all deliveries.